Staphylococcus aureus Capsular Polysaccharides

SUMMARY Serotype 5 and 8 capsular polysaccharides predominate among clinical isolates of Staphylococcus aureus. The results of experiments in animal models of infection have revealed that staphylococcal capsules are important in the pathogenesis of S. aureus infections. The capsule enhances staphylococcal virulence by impeding phagocytosis, resulting in bacterial persistence in the bloodstream of infected hosts. S. aureus capsules also promote abscess formation in rats. Although the capsule has been shown to modulate S. aureus adherence to endothelial surfaces in vitro, animal studies suggest that it also promotes bacterial colonization and persistence on mucosal surfaces. S. aureus capsular antigens are surface associated, limited in antigenic specificity, and highly conserved among clinical isolates. With the emergence of vancomycin-resistant S. aureus in the United States in 2002, new strategies are needed to combat staphylococcal infections. Purified serotype 5 and 8 capsular polysaccharides offer promise as target antigens for a vaccine to prevent staphylococcal infections, although the inclusion of other antigens is likely to be essential in the development of an effective S. aureus vaccine. The genetics and mechanisms of capsule biosynthesis are complex, and much work remains to enhance our understanding of capsule biosynthesis and its regulation.

[1]  A. Fattom,et al.  Prevalence of capsular serotypes among Staphylococcus aureus isolates from cows with mastitis in the United States. , 1997, Veterinary microbiology.

[2]  T. Evelyn Infection and Disease , 1996 .

[3]  K. Yoshida,et al.  Encapsulation by transformation of strains of Staphylococcus aureus determined by the serum-soft agar technique. , 1978, Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie.

[4]  R. Arbeit,et al.  Expression of capsular polysaccharide during experimental focal infection with Staphylococcus aureus. , 1987, The Journal of infectious diseases.

[5]  A. Lund,et al.  Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle. , 2001, Vaccine.

[6]  R. Arbeit,et al.  Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes , 1992, Infection and immunity.

[7]  D. Talan,et al.  Update on emerging infections: news from the Centers for Disease Control and Prevention. Syndromic surveillance for bioterrorism following the attacks on the World Trade Center--New York City, 2001. , 2002, Annals of emergency medicine.

[8]  J. Sun,et al.  Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureus , 1997, Journal of bacteriology.

[9]  R. Ekstedt Studies on immunity to staphylococcal infection in mice. IV. The role of specific and nonspecific immunity. , 1966, The Journal of infectious diseases.

[10]  B. Poutrel,et al.  Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains , 1995, Clinical and diagnostic laboratory immunology.

[11]  M. A. Melly,et al.  Biological Properties of the Encapsulated Staphylococcus aureus M , 1974, Infection and immunity.

[12]  C. Y. Lee Association of staphylococcal type-1 capsule-encoding genes with a discrete genetic element. , 1995, Gene.

[13]  L. Burrows,et al.  Functional Conservation of the Polysaccharide Biosynthetic Protein WbpM and Its Homologues in Pseudomonas aeruginosa and Other Medically Significant Bacteria , 2000, Infection and Immunity.

[14]  S. Fisher A heat stable protective staphylococcal antigen. , 1960, The Australian journal of experimental biology and medical science.

[15]  R. Byrd,et al.  Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. , 1990, Carbohydrate research.

[16]  S. Falkow,et al.  Loss of capsule expression by Haemophilus influenzae type b results in enhanced adherence to and invasion of human cells , 1991, Infection and immunity.

[17]  J. Fournier,et al.  Respiratory activity is essential for post-exponential-phase production of type 5 capsular polysaccharide by Staphylococcus aureus , 1996, Infection and immunity.

[18]  K. Amako,et al.  Distribution of capsular materials on the cell wall surface of strain Smith diffuse of Staphylococcus aureus , 1991, Journal of bacteriology.

[19]  K. B. Kiser,et al.  Staphylococcus aureus cap5P Encodes a UDP- N -Acetylglucosamine 2-Epimerase with Functional Redundancy , 1999, Journal of bacteriology.

[20]  Z. Cohn Determinants of Infection in the Peritoneal Cavity , 1962, The Yale journal of biology and medicine.

[21]  T. Donnelly,et al.  Susceptibility of laboratory rats, hamsters, and mice to wound infection with Staphylococcus aureus. , 1985, American journal of veterinary research.

[22]  Z. Cohn Determinants of infection in the peritoneal cavity. I. Response to and fate of Staphylococcus aureus and Staphylococcus albus in the mouse. , 1962 .

[23]  A. Fattom,et al.  Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides. , 1995, Vaccine.

[24]  J. Verhoef,et al.  Opsonic requirements for staphylococcal phagocytosis. Heterogeneity among strains. , 1977, Immunology.

[25]  A. Fattom,et al.  Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats , 1997, Infection and immunity.

[26]  C. Hellerqvist,et al.  The repeating sequence of the capsular polysaccharide of Staphylococcus aureus M. , 1983, Carbohydrate research.

[27]  C. Fred Fox,et al.  UCLA symposia on molecular and cellular biology , 1982 .

[28]  T. Luong,et al.  mgr, a Novel Global Regulator in Staphylococcus aureus , 2003, Journal of bacteriology.

[29]  K. B. Kiser,et al.  Staphylococcus aureus Cap5O Has UDP-ManNAc Dehydrogenase Activity and Is Essential for Capsule Expression , 2001, Infection and Immunity.

[30]  L. Grün A New Staphylococcal Antigen. , 1958 .

[31]  H. Verbrugh,et al.  Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. , 1982, Journal of immunology.

[32]  E. Gorak,et al.  Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  S. Sau,et al.  Regulation of Staphylococcus aureus Capsular Polysaccharide Expression by agr and sarA , 2002, Infection and Immunity.

[34]  S. Sau,et al.  The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. , 1997, Microbiology.

[35]  Jean C. Lee,et al.  Staphylococcus aureus Serotype 5 Capsular Polysaccharide Is Antiphagocytic and Enhances Bacterial Virulence in a Murine Bacteremia Model , 1998, Infection and Immunity.

[36]  Chia Y. Lee Cloning of genes affecting capsule expression in Staphylococcus aureus strain M , 1992, Molecular microbiology.

[37]  A. Fattom,et al.  Polysaccharide conjugate vaccines for the prevention of gram-positive bacterial infections. , 1996, Advances in experimental medicine and biology.

[38]  K. B. Kiser,et al.  Development and Characterization of aStaphylococcus aureus Nasal Colonization Model in Mice , 1999, Infection and Immunity.

[39]  A. Fattom,et al.  Capsular polysaccharide serotypes of coagulase-positive staphylococci associated with tenosynovitis, osteomyelitis, and other invasive infections in chickens and turkeys: evidence for new capsular types. , 1994, Avian diseases.

[40]  I. Pastan,et al.  Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A , 1993, Infection and immunity.

[41]  B. Poutrel,et al.  Type 5 and 8 capsular polysaccharides are expressed by Staphylococcus aureus isolates from rabbits, poultry, pigs, and horses , 1993, Journal of clinical microbiology.

[42]  J. N. Baldwin,et al.  Nature of the genetic determinant controlling encapsulation in Staphylococcus aureus Smith , 1977, Infection and immunity.

[43]  A. Boutonnier,et al.  Diagnosing Staphylococcus aureus endocarditis by detecting antibodies against S. aureus capsular polysaccharide types 5 and 8. , 1991, The Journal of infectious diseases.

[44]  C. A. Hopkins,et al.  Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid Staphylococcus aureus , 1987, Infection and immunity.

[45]  J. Goldberg Genetics of Bacterial Polysaccharides , 1999 .

[46]  J. Fournier,et al.  Staphylococcus aureus growth and type 5 capsular polysaccharide production in synthetic media , 1991, Applied and environmental microbiology.

[47]  J. Sarwar,et al.  A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge , 1996, Infection and immunity.

[48]  T. Luong,et al.  Overproduction of Type 8 Capsular Polysaccharide Augments Staphylococcus aureus Virulence , 2002, Infection and Immunity.

[49]  C. Wolz,et al.  Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis , 1988, Journal of clinical microbiology.

[50]  C. Wolz,et al.  Regulation of Staphylococcus aureus Type 5 and Type 8 Capsular Polysaccharides by CO2 , 2001, Journal of bacteriology.

[51]  C. Wolz,et al.  Adherence of Staphylococcus aureus to Endothelial Cells: Influence of Capsular Polysaccharide, Global Regulatoragr, and Bacterial Growth Phase , 2000, Infection and Immunity.

[52]  B. Poutrel,et al.  Immunogenicity in cows of Staphylococcus aureus type 5 capsular polysaccharide-ovalbumin conjugate. , 1994, Vaccine.

[53]  S. Black,et al.  Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.

[54]  Jane M. KUYPERSlt,et al.  Reduced Adherence to Traumatized Rat Heart Valves by a Low-Fibronectin-Binding Mutant of Staphylococcus aureus , 2022 .

[55]  J. Brisson,et al.  Three Highly Conserved Proteins Catalyze the Conversion of UDP-N-acetyl-d-glucosamine to Precursors for the Biosynthesis of O Antigen in Pseudomonas aeruginosaO11 and Capsule in Staphylococcus aureus Type 5 , 2003, The Journal of Biological Chemistry.

[56]  G. Moran,et al.  Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, MMWR. Morbidity and mortality weekly report.

[57]  R. Ekstedt Studies on Immunity to Staphylococcal Infection in Mice: I. Effect of Dosage, Viability, and Interval between Immunization and Challenge on Resistance to Infection Following Injection of Whole Cell Vaccines , 1963 .

[58]  C. A. Hopkins,et al.  Virulence studies, in mice, of transposon-induced mutants of Staphylococcus aureus differing in capsule size. , 1987, The Journal of infectious diseases.

[59]  P. Vanhems,et al.  Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients , 2002, The Lancet.

[60]  B. Poutrel,et al.  Immunogenicity in mice of multivalent conjugates composed of Staphylococcus aureus type 5 and 8 capsular polysaccharides and α- and β-toxins , 1996 .

[61]  Koenig Mg Factors relating to the Virulence of Staphylococci. I. Comparative Studies on Two Colonial Variants. , 1962 .

[62]  D. Liau,et al.  Structural analysis of the surface polysaccharide of Staphylococcus aureus M , 1977, Journal of bacteriology.

[63]  L. Steele-Moore,et al.  Capsule Expression by Bovine Isolates ofStaphylococcus aureus from Argentina: Genetic and Epidemiologic Analyses , 2000, Journal of Clinical Microbiology.

[64]  C. Nast,et al.  Regulation of Staphylococcus aureus type 5 capsular polysaccharides by agr and sarA in vitro and in an experimental endocarditis model. , 2002, Microbial pathogenesis.

[65]  J. Shiloach,et al.  Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. , 1996, Journal of the American Society of Nephrology : JASN.

[66]  K. Kenny,et al.  Genetic and Serologic Evaluation of Capsule Production by Bovine Mammary Isolates of Staphylococcus aureus and Other Staphylococcus spp. from Europe and the United States , 2000, Journal of Clinical Microbiology.

[67]  C. Bethel,et al.  Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility , 2000, The Pediatric infectious disease journal.

[68]  D. Stephens,et al.  Effect of the (alpha 2-->8)-linked polysialic acid capsule on adherence of Neisseria meningitidis to human mucosal cells. , 1993, The Journal of infectious diseases.

[69]  T. Foster,et al.  Genetic analysis of the cap5 locus of Staphylococcus aureus. , 1999, FEMS microbiology letters.

[70]  M. Bendinelli,et al.  Staphylococcus aureus Infection and Disease , 2001, Infectious Agents and Pathogenesis.

[71]  E. Kaplan,et al.  Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8 , 1987, Journal of clinical microbiology.

[72]  S. Ouyang,et al.  Type 1 Capsule Genes of Staphylococcus aureus Are Carried in a Staphylococcal Cassette Chromosome Genetic Element , 2002, Journal of bacteriology.

[73]  P. Peterson,et al.  Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes , 1978, Infection and immunity.

[74]  A. Frank,et al.  Increase in community-acquired methicillin-resistant Staphylococcus aureus in children. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  D. E. Rogers,et al.  FACTORS RELATING TO THE VIRULENCE OF STAPHYLOCOCCI , 1962, The Journal of experimental medicine.

[76]  M. Frank,et al.  Capsule Production and Growth Phase Influence Binding of Complement to Staphylococcus aureus , 2001, Infection and Immunity.

[77]  C. A. Hopkins,et al.  Purified capsular polysaccharide-induced immunity to Staphylococcus aureus infection. , 1988, The Journal of infectious diseases.

[78]  Isabella C Gilbert Dissociation in an Encapsulated Staphylococcus , 1931, Journal of bacteriology.

[79]  L. Baddour,et al.  Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis. , 1992, The Journal of infectious diseases.

[80]  G. Bellon,et al.  Regulation of Staphylococcus aureus capsular polysaccharide type 5: CO2 inhibition in vitro and in vivo. , 1997, The Journal of infectious diseases.

[81]  Channing,et al.  Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus , 1993, Infection and immunity.

[82]  F. Vandenesch,et al.  Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[83]  J. T. Park,et al.  Chemical Characterization of a New Surface Antigenic Polysaccharide from a Mutant of Staphylococcus aureus , 1971, Journal of bacteriology.

[84]  P. Sarradin,et al.  Heterogeneity of cell-associated CP5 expression on Staphylococcus aureus strains demonstrated by flow cytometry , 1997, Clinical and diagnostic laboratory immunology.

[85]  D. Greenberg,et al.  Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits , 1987, Infection and immunity.

[86]  G. Michel,et al.  Conjugation of capsular polysaccharide to alpha-haemolysin from Staphylococcus aureus as a glycoprotein antigen. , 1991, FEMS microbiology immunology.

[87]  I. Smith,et al.  Death from staphylococci in mice. , 1960 .

[88]  S. Hanessian,et al.  STRUCTURAL STUDIES ON STAPHYLOCOCCAL POLYSACCHARIDE ANTIGEN. , 1964, The Journal of biological chemistry.

[89]  H. Chambers,et al.  The changing epidemiology of Staphylococcus aureus? , 2001, Emerging infectious diseases.

[90]  T. Foster,et al.  Involvement of the accessory gene regulator (agr) in expression of type 5 capsular polysaccharide by Staphylococcus aureus. , 1993, Journal of general microbiology.

[91]  A. Sutton,et al.  Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes , 1988, Infection and immunity.

[92]  R. Arbeit,et al.  Virulence of Staphylococcus aureus mutants altered in type 5 capsule production , 1991, Infection and immunity.

[93]  A. Fox,et al.  Synthesis of Microcapsule by Staphylococcus aureus Is Not Responsive to Environmental Phosphate Concentrations , 1998, Infection and Immunity.

[94]  J. Fournier Capsular Polysaccharides of Staphylococcus aureus , 1990 .

[95]  A. Tarkowski,et al.  The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis , 1997, Infection and immunity.

[96]  L. Haaheim,et al.  Antibodies to staphylococcal peptidoglycan and its peptide epitopes, teichoic acid, and lipoteichoic acid in sera from blood donors and patients with staphylococcal infections , 1989, Journal of clinical microbiology.

[97]  J. Fournier,et al.  Isolation of type 5 capsular polysaccharide from Staphylococcus aureus. , 1987, Annales de l'Institut Pasteur. Microbiology.

[98]  Chia Y. Lee,et al.  Capsular polysaccharides of Staphylococcus aureus , 1999 .

[99]  G. Bellon,et al.  [Regulation of Staphylococcus aureus capsular polysaccharide type 5: in vitro and in vivo inhibition by CO2]. , 1997, Pneumologie.

[100]  S. Sau,et al.  Promoter Analysis of the cap8 Operon, Involved in Type 8 Capsular Polysaccharide Production in Staphylococcus aureus , 1999, Journal of bacteriology.

[101]  H. Verbrugh,et al.  Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections. , 1981, The Journal of infectious diseases.

[102]  J. Lee,et al.  Identification of a gene essential for O‐acetylation of the Staphylococcus aureus type 5 capsular polysaccharide , 1998, Molecular microbiology.

[103]  J. Shiloach,et al.  Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A , 1990, Infection and immunity.

[104]  D. E. Rogers,et al.  FACTORS RELATING TO THE VIRULENCE OF STAPHYLOCOCCI II. OBSERVATIONS ON FOUR MOUSE-PATHOGENIC STRAINS , 1962 .

[105]  J. Lam,et al.  Topological and functional characterization of WbpM, an inner membrane UDP‐GlcNAc C6 dehydratase essential for lipopolysaccharide biosynthesis in Pseudomonas aeruginosa , 2001, Molecular microbiology.

[106]  R. Ekstedt Studies on Immunity to Staphylococcal Infection in Mice. II. Effect of Immunization with Fractions of Staphylococcus aureus prepared by Physical and Chemical Methods. , 1963 .

[107]  A. Kligman,et al.  Experimental Staphylococcus aureus infections in humans. , 1971, The Journal of investigative dermatology.

[108]  H. Devlin,et al.  Its Preparation and Immunizing Activity against Experimental Infections , 1963, Nature.

[109]  A. C. Scott A capsulate Staphylococcus aureus. , 1969, Journal of medical microbiology.

[110]  M. Liu,et al.  Expression of type 8 capsular polysaccharide and production of toxic shock syndrome toxin 1 are associated among vaginal isolates of Staphylococcus aureus , 1990, Journal of clinical microbiology.

[111]  Robert E. Johnson,et al.  From the Centers for Disease Control. Staphylococcus aureus resistant to vancomycin--United States, 2002. , 2002, JAMA.

[112]  S. Ouyang,et al.  Transcriptional analysis of type 1 capsule genes in Staphylococcus aureus , 1997, Molecular microbiology.

[113]  R. Gibson,et al.  Group B streptococci invade endothelial cells: type III capsular polysaccharide attenuates invasion , 1993, Infection and immunity.

[114]  P. Rainard,et al.  Phagocytosis of Mastitis Isolates of Staphylococcus aureus and Expression of Type 5 Capsular Polysaccharide Are Influenced by Growth in the Presence of Milk , 1990, Journal of clinical microbiology.

[115]  P. François,et al.  Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis , 1995, Infection and immunity.

[116]  M. A. Melly,et al.  Biological Properties of the Encapsulated Staphylococcus aureus , 2022 .

[117]  J. Fournier,et al.  Production of type 5 capsular polysaccharide by Staphylococcus aureus grown in a semi-synthetic medium. , 1991, Journal of general microbiology.

[118]  R. Schneerson,et al.  Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types , 1985, Journal of clinical microbiology.

[119]  D. Goldmann,et al.  Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. , 1999, Science.

[120]  B. B. Wiley,et al.  CAPSULE PRODUCTION AND VIRULENCE AMONG STRAINS OF STAPHYLOCOCCUS AUREUS , 1974, Annals of the New York Academy of Sciences.

[121]  Chia Y. Lee,et al.  Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in Staphylococcus aureus , 1994, Journal of bacteriology.

[122]  R. Arbeit,et al.  Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. , 1984, Diagnostic microbiology and infectious disease.

[123]  S. Hensen,et al.  Location of Staphylococcus aureus within the experimentally infected bovine udder and the expression of capsular polysaccharide type 5 in situ. , 2000, Journal of dairy science.

[124]  Julia Y. Wang,et al.  Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[125]  R. H. Gorrill,et al.  The establishment of staphylococcal abscesses in the mouse kidney. , 1958, British journal of experimental pathology.

[126]  Jean C. Lee Capsule and Vaccine Development , 2001 .

[127]  J. C. Lee,et al.  Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis , 1995, Infection and immunity.

[128]  R. Arbeit,et al.  Capsular polysaccharide antigenemia in rats with experimental endocarditis due to Staphylococcus aureus. , 1987, The Journal of infectious diseases.

[129]  J. Fournier,et al.  Purification and characterization of Staphylococcus aureus type 8 capsular polysaccharide , 1984, Infection and immunity.

[130]  M. Frank,et al.  Availability of Complement Bound to Staphylococcus aureus To Interact with Membrane Complement Receptors Influences Efficiency of Phagocytosis , 2003, Infection and Immunity.

[131]  M. Daha,et al.  Participation of immunoglobulins and complement components in the intracellular killing of Staphylococcus aureus and Escherichia coli by human granulocytes , 1981, Infection and immunity.